General
prop 38：Prop 38: California’s $8.4 Billion Immunology Research Bond Explained
Proposition 38 would issue $8.4 billion in bonds for immunology research, splitting funds between a single specialized institute and competitive university grants, while requiring drug discounts and…
What Is Prop 38?
\n
Proposition 38, on the November 2026 California ballot, would authorize $8.4 billion in state general‑obligation bonds to fund immunology and immunotherapy research. The measure aims to accelerate treatments for cancer, heart disease, Alzheimer’s and other diseases that can be targeted through the immune system.
\n\n
Funding Breakdown
\n
Allocation of the Bond
\n
Half of the money—about $4.2 billion—is earmarked for a specialized research institute that meets strict criteria, including affiliation with a University of California campus that operates a medical center serving more than 3.5 million patients. The other half would be distributed as competitive grants to California universities and nonprofit research institutions through an advisory council.
\n
Revenue‑Sharing and Discount Requirements
\n
Any therapies developed with the bond funds must be offered to California patients at a 20 % discount. Ten percent of licensing revenue generated by the research is required to flow back to the state’s general fund, theoretically helping to offset bond repayments.
\n\n
Key Proponents and Funding Sources
\n
The measure was championed by billionaire philanthropist and medical inventor Gary K. Michelson, who provided the bulk of the campaign contributions. CalMatters reporting identified the California Institute for Immunology and Immunotherapy, co‑founded by Michelson, as the sole current entity that meets the eligibility requirements.
\n\n
Arguments in Favor
\n
- \n
- Patient advocates—including the Alzheimer’s Association, Michael J. Fox Foundation and American Nurses Association California—support the bond, saying it could accelerate life‑saving cures.
- Supporters argue the fund creates a stable source of financing as federal science funding faces potential cuts.
- The measure includes strict accountability measures: a 2 % cap on state administrative costs, public disclosure of spending, independent audits and a prohibition on for‑profit corporations receiving grants.
\n
\n
\n
\n\n
Arguments Against
\n
Financial Uncertainty
\n
Opponents note that the nonpartisan Legislative Analyst’s Office estimates the state would face annual repayment costs of roughly $500 million to $600 million for about 20 years, adding about 10 % more to the total cost due to interest. They argue that the projected 10 % revenue return is speculative and would require more than $120 billion in sales over two decades to fully offset the bond.
\n
Transparency and Concentration Concerns
\n
Critics point out that half the money would go to a single, unnamed institute, potentially limiting competition and raising questions about disclosure. The designated institute would be exempt from some California public‑records laws, a provision that has drawn particular scrutiny.
\n\n
Political Stance
\n
Tom Steyer, a prominent California Democrat, announced he will vote “no” on Proposition 38. In his ballot guide, Steyer argued the measure is too narrow and would favor a limited group of researchers rather than the broader scientific community.
\n\n
Fiscal Impact Summary
\n
If approved, the state’s general fund would incur an estimated net cost of $500 million to $600 million per year for roughly 20 years to service the bond. Offsetting revenue from licensing could reduce the net burden, but the timing and amount remain uncertain. The measure also includes indirect effects on programs like Medi‑Cal, depending on the price and adoption of new treatments.
\n\n
How Voters Can Decide
\n
Voters should weigh the potential for breakthrough therapies against the long‑term debt burden and the concentration of funding. The official voter information guide from the California Secretary of State and the nonpartisan Legislative Analyst’s Office provide detailed fiscal analyses and full text of the measure.
\n\n
The November 3, 2026 election will determine whether California becomes the first state to fund a dedicated immunology research bond of this scale.
